Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26200184 | 0.99 | TMPRSS2 (0.37) | TMPRSS2GSK3BDEGS1RAB9ASMN1; SMN2 | |
| SCHEMBL25925533 | 0.97 | TMPRSS2 (0.37) | TMPRSS2GSK3BRAB9ASMN1; SMN2HTT | |
| SCHEMBL25912349 | 0.94 | TMPRSS2 (0.38) | TMPRSS2 | |
| SCHEMBL25913910 | 0.89 | TMPRSS2 (0.37) | TMPRSS2SMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL25925050 | 0.89 | TMPRSS2 (0.37) | TMPRSS2RAB9ASMN1; SMN2NPC1L3MBTL1 | |
| SCHEMBL25913455 | 0.88 | TMPRSS2 (0.36) | TMPRSS2SMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL26546100 | 0.88 | DEGS1 (0.33) | TMPRSS2GSK3BDEGS1RAB9A | |
| SCHEMBL25912317 | 0.86 | TMPRSS2 (0.38) | TMPRSS2 | |
| SCHEMBL25912345 | 0.85 | TMPRSS2 (0.39) | TMPRSS2 | |
| SCHEMBL25913319 | 0.84 | TMPRSS2 (0.47) | TMPRSS2GSK3BRAB9ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054618-A1 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023239665-A1 | METHODS FOR TREATMENT OF VIRAL INFECTIONS INCLUDING SARS-COV-2 | GILEAD SCIENCES, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230322813-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023167938-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322813-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TMPRSS2 112/4885GSK3B 4102/4885DEGS1 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.